Roche Follow-On Development Strategy Highlighted By Strong 1H Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.